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Tumor necrosis factor-a receptor 1 and Fas recruit
overlapping signaling pathways. To clarify the differ-
ences between tumor necrosis factor a (TNFa) and Fas
pathways in hepatocyte apoptosis, primary mouse hepa-
tocytes were treated with TNFa or an agonist anti-Fas
antibody after infection with an adenovirus expressing
an IkB superrepressor (Ad5IkB). Treatment with TNFa
induced apoptosis in Ad5IkB-infected mouse hepato-
cytes, as we previously reported for rat hepatocytes.
Ad5IkB plus anti-Fas antibody or actinomycin D plus
anti-Fas antibody rapidly induced apoptosis, whereas
anti-Fas antibody alone produced little cytotoxicity. The
proteasome inhibitor (MG-132) and a dominant-negative
mutant of nuclear factor-kB-inducing kinase also pro-
moted TNFa- and Fas-mediated apoptosis. Expression of
either crmA or a dominant-negative mutant of the Fas-
associated death domain protein prevented TNFa- and
Fas-mediated apoptosis. In addition, the caspase inhib-
itors, DEVD-cho and IETD-fmk, inhibited TNFa- and
Fas-mediated apoptosis. In Ad5IkB-infected hepato-
cytes, caspases-3 and -8 were activated within 2 h after
treatment with anti-Fas antibody or within 6 h after
TNFa treatment. Confocal microscopy demonstrated on-
set of the mitochondrial permeability transition (MPT)
and mitochondrial depolarization by 2–3 h after anti-Fas
antibody treatment and 8–10 h after TNFa treatment,
followed by cytochrome c release. The combination of
the MPT inhibitors, cyclosporin A, and trifluoperazine,
protected Ad5IkB-infected hepatocytes from TNFa-me-
diated apoptosis. After anti-Fas antibody, cyclosporin A
and trifluoperazine decreased cytochrome c release but
did not prevent caspase-3 activation and cell-death. In
conclusion, nuclear factor-kB activation protects mouse
hepatocytes against both TNFa- and Fas-mediated apop-
tosis. TNFa and Fas recruit similar but nonidentical,
pathways signaling apoptosis. The MPT is obligatory for
TNFa-induced apoptosis. In Fas-mediated apoptosis, the
MPT accelerates the apoptogenic events but is not oblig-
atory for them.
Apoptosis, a morphologically and biochemically distinct form
of cell death, is an important physiologic process in both normal
development and in pathological processes. Two death factors,
Fas ligand and tumor necrosis factor-a (TNFa),1 bind to their
receptors and induce apoptosis, killing the cells within hours
(1). Apoptosis controlled by such death receptor pairs can cause
tissue destruction (2). Hepatocyte apoptosis, mainly induced by
death domain receptor ligands such as Fas ligand and TNFa, is
implicated in several experimental and human liver diseases
including viral hepatitis, alcoholic hepatitis, acute liver failure,
ischemia/reperfusion injury, diseases of the bile ducts, graft-
versus-host disease, and hepatocellular carcinoma (3).
The TNF receptor family includes Fas, the receptor for Fas
ligand, and the two TNFa receptors (TNFR) (1). Upon binding
to Fas ligand, Fas forms a complex with the associated protein,
Fas-associated death domain protein (FADD), which directly
binds and activates caspase-8. Recent studies showed that
FLICE-associated huge protein interacts with FADD and
caspase-8 (4). FLICE-associated huge protein may control ap-
optosis at the level of caspase activation. TNFR1 interacts with
the adaptor protein TNFR-associated death domain protein
(TRADD) that recruits FADD, which again directly activates
caspase-8. TNFa also induces other signaling pathways via
TRADD including the protein kinase receptor interacting pro-
tein and TNF receptor-associated factor 2 (TRAF2). TNFa ac-
tivates the mitogen-activated protein kinase kinase kinase,
NF-kB-inducing kinase (NIK), via either protein kinase recep-
tor interacting protein or TRAF2 (5, 6). NIK in turn phospho-
rylates and activates the IkB kinase (IKK) complex (7–9). IKKs
phosphorylate IkB, targeting it for NF-kB activation (10–12).
Recent studies indicate that NF-kB activation by TNFa pro-
tects cells from TNF cytotoxicity (13–15). TNFa binding to the
TNF receptor potentially both initiates apoptosis and activates
NF-kB, which suppresses apoptosis by induction of NF-kB-
responsive genes, including TRAF1, TRAF2, and the inhibitor
of apoptosis proteins (16). The expression of the IkB superre-
pressor by an IkBa (S32A, S36A)-expressing adenovirus
(Ad5IkB), which blocks NF-kB activation, sensitizes primary
rat hepatocytes to TNFa-mediated apoptosis (17). Further-
more, TNFa-mediated cytotoxicity is enhanced by the addition
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of inhibitors of protein or RNA synthesis (cyclohexamide and
actinomycin D) (18).
Fas induces NF-kB binding activity in certain, but not all,
cell types. Fas can stimulate the DNA binding activity of
NF-kB in a variety of tumor cells irrespective of their sensitiv-
ity or resistance to Fas-mediated cytotoxicity (19). Another
report showed that the activation of NF-kB can induce target
gene expression that rescues TNFa- but not Fas-mediated ap-
optosis in T24 cell lines (13). However, whether NF-kB is acti-
vated in Fas-mediated apoptosis in nontumor cells, such as
hepatocytes, is not clear. Anti-Fas antibody injection into mice
induces severe liver failure with apoptosis of hepatocytes (2).
However, anti-Fas antibody alone induces apoptosis in less
than 20% of the cultured hepatocytes in vitro, whereas all cells
were killed by anti-Fas antibody in the presence of actinomycin
D or cycloheximide (20, 21). These results suggest that cultured
mouse hepatocytes may express protective proteins against
apoptosis. Furthermore, Fas-mediated apoptosis was delayed
in hepatocytes during liver regeneration in mice (22). This
suggests that TNFa may act as one of the protective factors
against Fas-mediated hepatocyte apoptosis, because initiation
of liver regeneration requires TNFa. Perhaps TNFa-induced
activation of NF-kB protects hepatocytes from Fas-mediated
apoptosis.
Mitochondria play a key role in the regulation of apoptosis
(23–26). Opening of the mitochondrial permeability transition
(MPT) pore, which is regulated by members of the Bcl-2 family,
causes the release of soluble proteins, such as cytochrome c and
apoptosis-inducing factor, from the intermembrane space. In-
hibitors of MPT pore opening, including cyclosporin A (CsA),
block apoptosis in some systems (27, 28). The MPT is an essen-
tial component in the signaling pathways in TNFa-mediated
cytotoxicity in the L929 line of mouse fibroblast (29) and TNFa-
induced apoptosis in rat hepatocytes (17). Anti-apoptotic Bcl-2
family proteins reside in mitochondria and can prevent the
MPT. Bcl-xL/Bcl-2 prevented the release of cytochrome c, yet
other aspects of mitochondrial dysfunction still transpired and
cells died (30), suggesting that the release of cytochrome c may
not be required for cell death. Some studies using nonhepatic
cells demonstrate that the translocation of cytochrome c from
mitochondria to cytosol does not require a mitochondrial trans-
membrane depolarization (31–33), whereas others show that
mitochondrial depolarization accompanies cytochrome c re-
lease (34). Thus, mitochondrial involvement and the role of
cytochrome c and MPT in apoptosis are still controversial.
The purpose of this study was to elucidate the differences
between Fas and TNFa pathways in hepatocyte apoptosis and
the roles of NF-kB activation and MPT in Fas-mediated apop-
tosis. The results show that NF-kB activation has a protective
role in not only TNFa- but also Fas-mediated apoptosis. Fur-
thermore, we show that Fas agonistic antibody induces the
MPT, which accelerates apoptosis, but is not essential for it.
MATERIALS AND METHODS
Primary Hepatocyte Cultures—About 8-week-old C57Bl6 male mice
were anesthetized with ketamine/acepromazine malate administered
by intraperitoneal injection. Hepatocytes were then isolated by a retro-
grade, nonrecirculating in situ collagenase perfusion of livers cannulat-
ing through the inferior vena cava by a procedure modified from Mold-
eus et al. (35). Livers were first perfused in situ with an oxygenated 0.5
mM EGTA containing calcium-free salt solution (8 ml/min, 37 °C for 5
min), followed by perfusion with solution containing 0.04% collagenase
D (Roche Molecular Biochemicals) for 10 min. The liver was then gently
minced on a Petri dish and filtered with polyamide mesh (I 003 Y
NITEX 3–60/45, TETKO Inc., NY). Hepatocytes were washed two times
and centrifuged at 50 3 g for 2 min. Cell viability was consistently
.90% as determined by trypan blue exclusion. Hepatocyte cultures
contained less than 1% Kupffer cells and the stellate cells as deter-
mined by fluorescein isothiocyanate-labeled latex beads (1 mm, Poly-
sciences, Warrington, PA) and autofluorescence, respectively. 5 3 105
cells were plated on 6-well plates coated with mouse collagen type I in
Waymouth’s medium containing 10% fetal bovine serum, 0.1 mM insu-
lin, and 0.1 mM dexamethazone. 1.5 3 106, 2.5 3 106, or 8 3 106 cells
were plated on a 60-, 100-, or 150-mm dish, respectively. After 2 h, the
culture was washed with phosphate-buffered saline and changed to
hormonally defined medium (HDM) containing 0.1 mM insulin, 2 mM
L-glutamine, 5 mg/ml transferrin, 3 mM selenium, and 10 nM free fatty
acids in RPMI basal medium. Cells were infected with recombinant
adenoviruses in HDM containing 30 plaque-forming units/cell for 2 h at
37 °C and then changed to HDM containing recombinant murine TNFa
(R&D Systems, Minneapolis, MN), Jo-2 (Pharmingen, San Diego, CA),
or other treatments. All animals received humane care in compliance
with the guidelines of the University of North Carolina.
Adenoviruses—The adenovirus 5 variants Ad5IkB, Ad5LacZ,
Ad5DFADD and Ad5crmA, expressing HA-IkBa (S32A, S36A), b-galac-
tosidase, a truncated form of FADD, and crmA, respectively, have been
described elsewhere (17, 36). The Ad5 vector expressing DNIK (Ad5D
NIK) was constructed by cre-lox recombination as described (37). An
insert from pCDNA-HA2101 (deletion of amino acids 1–623, a gift from
Dr. G. Natoli) (6) was subcloned into the shuttle vector pAdlox using
standard techniques, and the construct was confirmed by restriction
digests. Expression of the DNIK construct was confirmed with a lucif-
erase reporter gene assay in monkey kidney fibroblasts (COS-7, ATCC-
CRL-1651, American Type Culture Collections) as described previously
(36) and Western blotting using a mouse anti-HA monoclonal antibody
(Babco, Berkeley, CA). Briefly, When COS cells reached subconfluence
on 6-well culture plates, the cells were transfected with 3 mg of DNA
and 1 mg of (kB)3-Luc, a reporter plasmid containing three copies of the
NF-kB binding site (38), using LipofectAMINE (Life Technologies, Inc.).
Twenty-four h after transfection, medium was replaced with Dulbecco’s
modified Eagle’s medium containing 10% fetal bovine serum with or
without 20 ng/ml of TNFa. After a 5-h incubation, cellular extracts were
prepared using enhanced luciferase assay reagents (Analytical Lumi-
nescence, San Diego, CA). Some cells were infected with Ad5DNIK 24 h
after transfection of (kB)3-Luc, were stimulated, and were harvested as
described the above.
Measurement of Apoptosis—For quantitation of cell viability (pre-
sented as mean 6 S.E.), cells were infected and treated as described
above. After 17–20 h of TNFa or Jo-2 treatment, cell viability was
determined by exclusion of trypan blue. Viable cells were counted in
three different 2003 power fields, and the percentage of treated viable
cells to untreated viable cells was determined as a percentage of control
viability. For propidium iodide nuclear staining, cells were fixed in 3:1
methanol/acetic acid, stained with 10 mg/ml popidium iodide, and
viewed with an Olympus fluorescence microscope using a rhodamine
filter set. Hepatocyte cell death was confirmed as apoptosis by terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling
(TUNEL) (Roche Molecular Biochemicals). TUNEL staining was per-
formed according to the manufacture’s instructions. Positive (apoptotic)
cells were counted in three different 2003 power fields. To assess DNA
ladder formation, 2 3 106 cells were digested overnight at 37 °C in 0.5
mg/ml proteinase K, 0.5% sarcosyl in phosphate-buffered saline, treated
with 10 mg of RNase for 1 h at 37 °C, gently extracted with phenol and
chloroform, and analyzed on 2% agarose gels. Amino-4-trifluoromethyl
courmarin (AFC) release assays for caspase-3 and -8 activities were
performed using the FluorAce kit (Bio-Rad) according to the manufac-
turer’s instructions. Briefly, whole cell lysates were combined with 25
mM z-DEVD-AFC or IETD-AFC (Enzyme and Systems Products, Liver-
more, CA) and were incubated 2 h at 37 °C. The change in fluorescence
(excitation at 370 nm and emission at 490 nm) was monitored at 1-h
intervals, converted to picomoles of AFC released by using a standard
curve, and normalized for protein concentration.
Nuclear Extract Preparation and Electrophoretic Mobility Shift As-
say—Nuclear protein extracts were prepared from primary mouse
hepatocytes as described previously (17, 36). Protein-DNA binding re-
actions were carried out for 20 min on ice using 5 mg of nuclear extract
and 32P-labeled DNA probes for the NF-kB consensus binding site (39).
Complexes were separated by electrophoresis on nondenaturing 5%
acrylamide gels and assayed by autoradiography and PhosphorImager
analysis (Molecular Dynamics, Sunnyvale, CA). For supershift assays,
8 mg of antibody against p65 or p50 subunit of the NF-kB complex
(Santa Cruz Biotechnology, Santa Cruz, CA) were added to the reaction
mixture, and the incubation time was extended for an additional 30
min.
Western Blot Analysis for Cytochrome c—The preparation of cytosolic
S100-fractions and Western blot analysis was performed as described
previously (17). Briefly, S-100 fractions were prepared from 8 3 106
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hepatocytes by differential centrifugation in buffer containing 250 mM
sucrose. Lysates containing 25 mg of protein was separated by electro-
phoresis on 15% acrylamide SDS gels and transferred into nitocellulose
membranes (Schleicher & Schuell). Equal loading was confirmed by
Ponceau S staining. Cytochrome c was detected using primary mono-
clonal anti-cytochrome c antibody (Pharmingen, San Diego, CA) and
secondary anti-mouse horseradish peroxidase-conjugated antibody
(Santa Cruz Biotechnology). Proteins were detected with ECL detection
reagents (Amersham Pharmacia Biotech).
Confocal Microscopy—Cell loading and confocal microscopy were car-
ried out as described previously (40). Briefly, 1–2 3 106 hepatocytes
plated on collagen-coated 40-mm-diameter glass coverslips were in-
fected with Ad5IkB in HDM supplemented with 50 mM HEPES (pH 7.0)
to stabilize pH during the confocal measurements. The cells were
loaded with 250 nM tetramethylrhodamine methyl ester (TMRM, Mo-
lecular Probes, Eugene, OR) and 1 mM calcein-acetoxymethyl ester
(Molecular Probes) in Krebs Ringer-Hepes buffer for 15 min at 37 °C.
The coverslips were mounted on a Nikon microscope (Nikon, Melville,
NY) in HDM-HEPES containing 100 nM TMRM, and the temperature
was maintained at 37 °C. The first image (time point 0) was then
recorded. Subsequently, TNFa or Jo-2 was added to the medium, and
images were collected at given time-points. Calcein and TMRM fluores-
cence were excited with an argon laser through a double dichroic re-
flector at 488 and 568 nm, respectively. TMRM was imaged through a
590-nm-long path emission filter using a Bio-Rad MRC-600 confocal
system (Bio-Rad). Calcein fluorescence was collected through a 515–
560-nm band path emission filter. A numerical aperture 1.4, 603 ob-
jective lens was used, and pinholes were set to 4 in both channels. Laser
attenuation and power were set at 0.3% and low, respectively.
RESULTS
The IkB Superrepressor Sensitizes Mouse Hepatocytes to
TNFa- and Fas-mediated Apoptosis—Hepatocytes are resist-
ant to TNFa-mediated apoptosis unless they are also treated
with an inhibitor of protein synthesis (i.e. cycloheximide), RNA
synthesis (i.e. actinomycin D) (18, 41), or NF-kB activity (i.e. an
IkB superrepressor) (17). To extend these studies into Fas-
mediated apoptosis, we switched to primary cultures of adult
mouse hepatocytes, because rat hepatocytes only express low
levels of Fas (42). TNFa alone had no cytotoxicity in primary
mouse hepatocytes, but actinomycin D (ActD) plus TNFa
caused massive cell death (Fig. 1, 16.2 6 0.4%, % control
viability at 17 h after treatment). Also, treatment of Ad5IkB-
infected mouse hepatocytes expressing the IkB superrepressor
with TNFa induced cell death (12.0 6 1.1%). Cells expressing
IkB superrepressor but not treated with TNFa did not lose
viability. Furthermore, Ad5LacZ had a minimal effect on cell
viability after TNFa treatment (82.0 6 2.5%), compared with
noninfected hepatocytes after TNFa.
To study the role of NF-kB activation on Fas-mediated ap-
optosis, we treated cells with anti-Fas agonist-like antibody
Jo2. Ad5IkB plus Jo2 (12.0 6 1.2%) or ActD plus Jo2 (8.7 6
0.9%) rapidly induced massive cell death, whereas Jo2 alone
had low cytotoxicity (78.0 6 11.5%). Furthermore, Jo2 did not
induce significant cell death in Ad5LacZ-infected hepatocytes
(75.0 6 1.1%). The cytotoxic effects of Jo2 were dose-dependent
in mouse hepatocytes expressing the IkB superrepressor (data
not shown). The Ad5IkB-infected hepatocytes treated with Jo2
displayed nuclear condensation and fragmentation by pro-
pidium iodide staining, characteristic of apoptosis (Fig. 2A,
lower panel), whereas uninfected cells displayed normal nu-
clear morphology after Jo2 treatment (Fig. 2A, upper panel). To
confirm hepatocyte death as apoptosis, TUNEL assay was per-
formed. Although TUNEL positive cells were minimal after
TNFa or Jo2 treatment, significant positive hepatocytes were
observed after TNFa or Jo2 treatment in ActD-sensitized or
Ad5IkB-infected hepatocytes (Fig. 2B). These results were con-
sistent with cytotoxicity determined by the trypan blue extrac-
FIG. 1. The IkB superrepressor sensitizes mouse hepatocytes
to TNFa- and Fas-mediated cell death. Primary mouse hepatocytes
were treated with TNFa (30 ng/ml) or Jo2 (0.5 mg/ml) after Ad5IkB
infection (30 m.o.i.). Some cells were pretreated with ActD (0.2 mg/ml) or
MG132 (20 mM). Cell viability was assessed after 17 h by a trypan blue
exclusion test. Data are shown as average percent viability 6 S.E. of
two to four different experiments.
FIG. 2. The IkB superrepressor sensitizes mouse hepatocytes
to TNFa- and Fas-mediated apoptosis. A, propidium iodide-stained
images of noninfected (upper panel), and Ad5IkB-infected cells (lower
panel) at 12 h after Jo2 treatment (original magnification of 3600).
Arrows indicate representative apoptotic nuclei. B, TUNEL assay per-
formed at 13 h after treatment. Apoptotic positive cells were counted in
three different 2003 power fields. Data are shown as average positive
cells 6 S.E. of two different experiments. C, DNA ladder assay from
cultured hepatocytes (2 3 106 cells) collected 19 h after treatment.
Cytosolic DNA was isolated and subjected to 2% agarose gel
electrophoresis.
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tion test. Furthermore, apoptosis was confirmed by the detec-
tion of fragmented chromosome DNA in infected cells after
exposure to TNFa or Jo2 (Fig. 2C). However, no DNA fragmen-
tation was observed in the uninfected cells after Jo2 treatment.
We also documented the role of the IkB/NFkB system in TNFa-
and Fas-mediated apoptosis with a proteasome inhibitor, be-
cause proteasome inhibitors block IkBa degradation and re-
duce NF-kB activation (43). MG-132, a potent and specific
proteasome inhibitor (Fig. 1, MG-132 alone, 92.0 6 4.6%),
promotes TNFa- and Fas-mediated apoptosis (9.0 6 3.6% and
0%, respectively).
To examine whether Jo2 directly activates NF-kB, NF-kB
DNA binding activity was assessed by electrophoretic mobility
shift assay using an NF-kB binding site as probe. TNFa treat-
ment for 30 min induced an increase in NF-kB DNA binding
activity (2.2-fold increase, p , 0.001, versus untreated hepato-
cytes) (Fig. 3, A and B). Jo2 treatment also induced NF-kB
binding activity (1.5-fold increase, p , 0.005, versus untreated
hepatocytes), although to a less extent than TNFa. This acti-
vation was observed even at 15 min after Jo2 treatment with
the peak at 30 min after Jo2 (data not shown). The NF-kB
complex activated by Jo2 treatment of mouse hepatocytes was
composed of p50-p65 dimers, as determined by supershifts (Fig.
3A). These results show that TNFa and Jo2 activate NF-kB in
mouse hepatocytes and blocking NF-kB sensitizes mouse hepa-
tocytes to TNFa- and Fas-mediated apoptosis.
Overexpression of Dominant-Negative Mutant NIK Sensitizes
Hepatocytes to TNFa- and Fas-mediated Apoptosis—NIK has
been identified as a TRAF2-interacting protein that signals for
NF-kB activation (5). Adenovirus (Ad5DNIK)-mediated overex-
pression of the C-terminal NIK fragment (NIKD2101) impaired
the induction of NF-kB by TNFa in a reporter gene assay in
COS cells (Fig. 3C). HA-tagged DNIK was expressed in primary
mouse hepatocytes by infection of Ad5DNIK at 10, 30, and
50 m.o.i. (Fig. 3D). Dominant-negative expression of NIK sen-
sitized mouse hepatocytes to TNFa- and Fas-mediated cell
death (Fig. 3E). Cell death by apoptosis was confirmed by
TUNEL assay (31.7 6 1.7, 45.0 6 3.2, TUNEL positive cells/
2003 power field 13 h after TNFa or Jo2 treatment in AdDNIK-
infected hepatocytes, respectively). These results support a
protective role for NF-kB activation in TNFa- and Fas-medi-
ated apoptosis and that NIK is required for the activation of
NF-kB by TNFa or Fas.
TNFa and Jo2 Induce Caspase Activation in Ad5IkB-infected
Hepatocytes with Different Time Courses—To compare TNFa
and Fas signaling pathways in hepatocyte apoptosis, time
courses for caspase-3 and casapase-8 activation were deter-
mined. Ad5IkB-infected hepatocytes were treated with TNFa
(30 ng/ml) or Jo2 (0.5 mg/ml) and then lysed and assayed for
FIG. 4. TNFa and Jo2 activate caspase-3 and -8 in Ad5IkB-
infected hepatocytes with different time courses. Ad5IkB-in-
fected hepatocytes were treated with TNFa (30 ng/ml) or Jo2 (0.5 mg/ml)
and then lysed and assayed for caspase 3 and 8 activity (A and B,
respectively) at 1-h intervals. Data are shown as average fold increases
of basal levels without treatment 6 S.E. of three different experiments
performed in duplicate.FIG. 3. TNFa or Fas activates NF-kB in primary mouse hepa-tocytes and overexpression of dominant-negative mutant NIK
sensitizes hepatocyte to TNFa- or Fas-mediated cell death. A,
NF-kB DNA binding activity was assessed by an electrophoretic mobil-
ity shift assay using NF-kB binding sites as the probe with nuclear
extracts prepared after a 30-min incubation with TNFa or Jo2. For
supershift assays, 8 mg of antibody against the p65 or p50 subunit of the
NF-kB complex were added to the reaction mixture, and the incubation
time was extended for an additional 30 min. B, band intensity was
quantified using phosphoimager analysis. Data are shown as mean of
net cpm 6 S.E. of three different experiments. C, a reporter gene assay
was performed using (kB)3-luc. NF-kB activation was induced by a 5-h
incubation with 20 ng/ml TNFa. Results from one representative ex-
periment performed in duplicate are shown. D, the HA-tagged DNIK
was detected by Western blotting using anti-HA antibody in whole
extracts after Ad5DNIK infection. E, Ad5DNIK-infected hepatocytes
were untreated or treated with TNFa (30 ng/ml) or Jo2 (0.5 mg/ml). Cell
viability was assessed after 17 h by trypan blue exclusion test. Data are
shown as average percent viability compared with uninfected cells
(con) 6 S.E. of three different experiments.
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caspase-3 and caspase-8. Caspase-3 was activated 11-fold for
6 h after TNFa treatment with the peak of the activity of
41-fold at 16 h after treatment (Fig. 4A). Caspase-8 was acti-
vated 14-fold at 8 h. In Jo2-treated hepatocytes expressing the
IkB superrepressor, caspase-3 was activated 32-fold at 90 min
after treatment, with the peak of 69-fold at 8 h after treatment
(Fig. 4B). Also, a distinct early peak of caspase-8 activation was
observed 90 min after Jo2 treatment. At later time points,
caspase-8 was induced to higher levels by TNFa than Fas.
These results show that these caspases were activated in both
TNFa- and Fas-mediated apoptosis but that Fas activated
caspases earlier than TNFa.
DFADD, crmA, and Caspase Inhibitors Block TNFa- and
Fas-mediated Cell Death in Ad5IkB-infected Hepatocytes—To
investigate the involvement of apoptotic signals from the com-
plexes of TNFRzTRADDzFADD and FaszFADD and the role of
proximal caspases, primary mouse hepatocytes were infected
with Ad5IkB together with Ad5DFADD (30 m.o.i.) or Ad5crmA
(30 m.o.i.) and then treated with TNFa (30 ng/ml) or Jo2 (0.5
mg/ml). Ad5DFADD expresses a truncated, dominant-negative
mutant of FADD (44). Ad5crmA expresses crmA, a serpin in-
hibitor of a subset of caspases including caspases-1 and -8 (45,
46). Adenovirus-mediated expression of DFADD and crmA pre-
vents TNFa- and Fas-mediated apoptosis (Fig. 5). To assess the
role of apoptotic protease cascade in hepatocyte apoptosis, cells
were treated with DEVD-cho (50 mM)(an inhibitor of caspase 3)
or IETD-fmk (50 nM)(an inhibitor of caspases-4, -5, and -8)
together with TNFa (30 ng/ml) or Jo2 (0.5 mg/ml). Caspase
inhibitors, DEVD-cho or IETD-fmk, clearly inhibit TNFa- and
Fas-mediated apoptosis (Fig. 5). These results indicate that
Fas and TNFR1 appear to utilize similar or at least partially
overlapping pathways including FADD, caspase-3, caspase-8,
and/or caspase-1.
TNFa and Jo2 Induce the MPT and Mitochondrial Depolar-
ization in Ad5IkB-infected Hepatocytes with Different Time
Courses—Primary mouse hepatocytes were treated with TNFa
(30 ng/ml) or Jo2 (0.5 mg/ml) after Ad5IkB infection (30 m.o.i.)
and then loaded with calcein to monitor the MPT and TMRM to
monitor mitochondrial depolarization. Their fluorescence was
monitored simultaneously in living cells on a heated platform
by confocal microscopy. Before treatment with Jo2, each
TMRM-labeled mitochondrion corresponded to a dark void in
the calcein image, showing that the mitochondria were polar-
ized and impermeable to low molecular weight solutes (Fig. 6,
upper left panel). At 3 h after treatment of Jo2, some mitochon-
dria filled with calcein fluorescence (Fig. 6, middle left panel),
demonstrating permeabilization of the inner mitochondrial
membrane, corresponding to the onset of the MPT. Simulta-
neously, these mitochondria lost TMRM fluorescence, indicat-
ing depolarization (Fig. 6, middle right panel). Finally, after
3.5 h of exposure to Jo2, there was hepatotoxicity with extrav-
asation of calcein (Fig. 6, lower left panel). In contrast to Jo2
treatment, TNFa treatment induced MPT and mitochondrial
depolarization at 8–10 h in mouse hepatocytes (data not
shown). This TNFa result was similar to previous studies in
primary rat hepatocytes (17). These results show that MPT is
induced in both TNFa- and Jo2-mediated apoptosis but at
different time courses.
The Combination of CsA and Trifluoperazine (TFZ) Blocks
TNFa- but Not Fas-mediated Cell Death in Ad5IkB-infected
Hepatocytes—CsA, an immunosuppressive cyclic oligopeptide,
specifically blocks the MPT and has been shown to prevent cell
injury in several kinds of models (40, 47). TFZ also blocks the
MPT and prevents mitochondrial depolarization, ATP deple-
tion, and cell death (48). Hepatocytes overexpressing IkB su-
perrepressor were treated with TNFa or Jo2 in the presence of
CsA (5 mM) and TFZ (12.5 mM). Confocal studies showed that
TMRM and calcein distributions did not change between 8 (Fig.
7A) and 12 h (Fig. 7B) in TNFa-treated hepatocytes. Similarly,
these distributions did not change between 7 (Fig. 7C) and 13 h
(Fig. 7D) in Jo2-treated hepatocytes. These results indicate
FIG. 5. DFADD, crmA, and caspase inhibitors block TNFa- and
Fas-mediated cell death in Ad5IkB-infected hepatocytes. Pri-
mary mouse hepatocytes were infected with Ad5IkB and then treated
with TNFa (30 ng/ml) or Jo2 (0.5 mg/ml). Some hepatocytes were in-
fected with Ad5DFADD (30 m.o.i.) or Ad5CrmA (30 m.o.i.) or also
treated with DEVD-cho (50 mM) or IETD-fmk (50 nM). Cell viability was
assessed after a 17-h treatment by a trypan blue exclusion test. Data
are shown as average percent viability 6 S.E.
FIG. 6. Jo2 induces the MPT and mitochondrial depolarization
in Ad5IkB-infected hepatocytes. Primary mouse hepatocytes were
treated with Jo2 (0.5 mg/ml) after Ad5IkB infection (30 m.o.i.) and then
loaded with calcein (left panel) to monitor the MPT and TMRM (right
panel) to monitor mitochondrial depolarization. Calcein and TMRM
fluorescence was monitored simultaneously over time in living cells by
confocal microscopy.
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that CsA plus TFZ block mitochondrial depolarization and
MPT in TNFa- and Fas-treated hepatocytes.
To test the ability of CsA plus TFZ to protect against TNFa-
and Fas-mediated apoptosis, primary mouse hepatocytes were
infected with Ad5IkB and then treated with TNFa (30 ng/ml) or
Jo2 (0.5 mg/ml) with and without CsA (5 mM) and/or TFZ (12.5
mM). CsA alone partially inhibits TNFa- and Fas-mediated
apoptosis (Fig. 8A). Furthermore, the combination of CsA and
TFZ significantly protects Ad5IkB-infected hepatocytes from
TNFa-mediated apoptosis but not from Fas-mediated apopto-
sis. Although multiple concentrations of CsA (1–10 mM) and
TFZ (2.5–25 mM) were tested, the maximal protective effect of
CsA plus TFZ on TNFa- and Fas-mediated apoptosis were
observed at the above concentrations.
MPT Accelerates Fas-mediated Apoptosis—Our previous
study showed that the MPT is required for TNFa-mediated
cytochrome c release and subsequent apoptosis in rat hepato-
cytes (17). CsA plus TFZ blocked the TNFa-mediated MPT
(Fig. 7, A and B) and cell death (Fig. 8A) in mouse hepatocytes
overexpressing the IkB superrepressor. Although CsA plus
TFZ blocked the Fas-mediated MPT (Fig. 7, C and D), cell
death still occurred (Fig. 8A). Therefore, to assess the relation-
ship between MPT and cytochrome c release, S-100 fractions
were prepared from TNFa- or Jo2-treated hepatocytes overex-
pressing IkB superrepressor with or without CsA plus TFZ.
Primary mouse hepatocytes were treated with TNFa (30 ng/ml)
or Jo2 (0.5 mg/ml) after Ad5IkB infection (30 m.o.i.). S-100
fractions were analyzed for cytochrome c content by Western
blotting. TNFa induced cytochrome c release into the cyto-
plasm at 6 h after treatment (Fig. 8B). Jo2 induced cytochrome
c release at 2 h and peaks at 4 h after treatment (Fig. 8B).
Thus, cytochrome c release follows the MPT in AdIkB-infected
hepatocytes after Jo2 exposure. The treatment of CsA plus TFZ
substantially decreased cytochrome c release at 2 or 4 h after
Jo2 treatment (Fig. 8B), whereas CsA plus TFZ completely
blocked TNFa-mediated cytochrome c release (Fig. 8B). How-
ever, CsA alone or TFZ alone had no effect on blocking cyto-
chrome c release in TNFa- or Fas-mediated apoptosis (Fig. 8C).
In addition to cytochrome c release, caspase-3 activation was
suppressed at early time points after Jo2 treatment in hepato-
cytes treated with CsA plus TFZ (Fig. 9A). CsA plus TFZ
blocked 70% of TNFa-induced cell death in Ad5IkB-infected
hepatocytes even at 24 h after treatment (Fig. 9B). Treatment
of CsA plus TFZ delayed the time of 50% Fas-mediated cell
death from about 8 to about 20 h (Fig. 9C). Furthermore,
confocal studies demonstrated that bleb formation and cell
shrinkage was observed at 16–18 h after Jo2 treatment despite
blocking the MPT (Fig. 9D), whereas some mitochondria re-
mained polarized. These results indicate that although the
MPT is not required for Fas-mediated apoptosis in hepatocytes,
the MPT accelerates the progression of apoptotic cell killing.
DISCUSSION
Fas agonistic antibody (Jo2) and TNF-a are potent mediators
of hepatoxicity in vivo and in cultured cells. In the present
study, we demonstrated that (a) inhibition of NF-kB activation
by the IkB superrepressor by a proteasome inhibitor or by a
dominant-negative NIK sensitizes mouse hepatocytes to TNFa-
and Fas-mediated apoptosis; (b) both TNFa and Fas activates
NF-kB in primary mouse hepatocytes; (c) TNFa and Fas recruit
similar pathways including FADD, the activation of caspase-3
and caspase-8, the MPT, and cytochrome c release, but the Fas
signaling pathway for apoptosis is more rapid; (d) inhibition of
the MPT with CsA and TFZ blocks TNFa-mediated apoptosis,
but delays rather than prevents Fas-mediated apoptosis; and
(e) inhibition of MPT markedly decreases cytochrome c release
and delays caspase-3 activation in Fas-mediated apoptosis.
These observations suggest that two pathways contribute to
Fas-mediated apoptosis and that the MPT contributes to an
early and more rapid pathway to apoptotic cell killing (Fig. 10).
Anti-Fas antibody (Jo2) injection rapidly induces massive
hepatocyte apoptosis in mice in vivo (2). Nevertheless, many
studies using cultured mouse hepatocytes have shown that
Fas-mediated apoptosis requires the presence of an inhibitor of
translation (cycloheximide), an inhibitor of RNA synthesis (ac-
tinomycin D), or a protein kinase inhibitor (H7) (20, 21). Con-
sistent with these reports, anti-Fas antibody alone has very low
cytotoxicity in cultured mouse hepatocytes, whereas Act D
sensitizes hepatocytes to Fas-mediated apoptosis in this study
(Fig. 1). These results suggest that cultured mouse hepatocytes
may express protective proteins against apoptosis from Fas-
mediated apoptosis. NF-kB activation prevents TNFa toxicity
in many cell types (13–15), including hepatocytes (49). Thus we
hypothesized that NF-kB may also protect primary mouse
hepatocytes from Fas-mediated apoptosis.
NF-kB is sequestered in the cytoplasm by inhibitory pro-
teins, such as IkBa, which mask the nuclear localization signal
of NF-kB (50). The phosphorylation of two serines 32 and 36 of
IkBa by the IKK complex, which includes IKKa, IKKb, and
IKKg, triggers polyubiquitination of IkB proteins, which tar-
gets them for rapid proteasome-dependent degradation (7, 8,
10–12, 51). The loss of IkB binding allows NF-kB to translocate
to the nucleus and activate NF-kB-dependent transcription. In
this study we selected three methods for inhibition of NF-kB
activation: adenovirus-mediated expression of an IkB superre-
pressor and a dominant-negative mutant NIK, and a protea-
some inhibitor, MG-132. Inhibition of NF-kB activation by any
of these methods clearly sensitizes mouse hepatocytes to
TNFa- and Fas-mediated apoptosis, whereas these treatments
without TNFa or Fas stimulation have no significant cytotox-
icity (Figs. 1, 2B, and 3E). Furthermore, mobility shift assays
indicate that Jo2 induces NF-kB DNA binding activity (1.5-fold
increase) in cultured mouse hepatocytes, even though this ac-
tivity was weaker than TNFa-induced NF-kB DNA binding
activity (2.2-fold increase) (Fig. 2B). This TNFa-induced NF-kB
DNA binding activity is comparable to that in myocytes (2.1-
fold increase) (52). These results suggest that Fas increases
FIG. 7. CsA plus TFZ blocks the MPT induced by TNFa or Jo2.
Primary mouse hepatocytes were treated with TNFa (30 ng/ml) or Jo2
(0.5 mg/ml) with CsA (5 mM) plus TFZ (12.5 mM) after Ad5IkB infection
(30 m.o.i.) and then loaded with calcein to monitor the MPT and TMRM
to monitor mitochondrial depolarization. These fluorescences were
monitored simultaneously over time in living cells by confocal micros-
copy. A and B, 8 and 12 h after TNFa treatment, respectively. C and D,
7 and 13 h after Jo2 treatment, respectively.
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NF-kB DNA binding activity, which is mediated by activated
NIK, activated IKK, phosphorylated IkB, and subsequent IkB
degradation by proteasomes with translocation of NF-kB to the
nucleus. A previous study showed that Fas stimulates the DNA
binding activity of NF-kB in a variety of cells, irrespective of
their sensitivity or resistance to Fas-mediated cytotoxicity (19).
However, in our study, NF-kB activation had a protective effect
in Fas-mediated apoptosis in cultured mouse hepatocytes.
One of the protective proteins against apoptosis is inducible
nitric-oxide synthases. NO prevents apoptosis by suppressing
the increase of caspase-3-like activity (53). NO-mediating S-
nitrosylation of the cysteine-containing enzymes that mediate
apoptosis may regulate the balance between apoptosis and
necrosis (54). The mRNA of inducible nitric-oxide synthases is
regulated by NF-kB, and NO prevents hepatocyte apoptosis
initiated by the removal of growth factors or exposure to TNFa
or anti-Fas antibody (55–57). Therefore, inducible nitric-oxide
synthases might be an NF-kB-inducible protective gene medi-
ating resistance to TNFa and Fas cytotoxicity.
Ceramides have been implicated as a second messenger in
signaling pathways leading to apoptosis (58–61). A recent pa-
per showed that primary rat hepatocytes are resistant to cer-
amide-induced toxicity (62). However, NFkB inactivation or
ActD sensitize a rat hepatocyte cell line to ceramide toxicity,
suggesting that ceramide may act as a downstream mediator of
TNFa toxicity. On the other hand, it has been reported that
GD3 ganglioside, a product of ceramide, is required for Fas-
and ceramide-induced apoptosis (63), induces the MPT and
apoptosis in rat hepatoma cells (64), and directly induces the
MPT in isolated liver mitochondria (64, 65). Although signifi-
cant cell-type-specific differences exist in cell death pathway,
further investigations will determine the relationship between
Fas, ceramides, and the MPT in hepatocytes.
A recent study defined two pathways for Fas-mediated ap-
optosis in different cell types (66). In type I cells, caspase-8 is
activated within seconds and caspase-3 within 30 min, whereas
in type II cells cleavage of caspases is relatively delayed. Both
cells showed similar Fas-mediated apoptosis and loss of mito-
chondrial transmembrane potential, but only in type II cells
does overexpression of Bcl-2 or Bcl-xL block caspase-8 and
caspase-3 activation as well as apoptosis, indicating type II
cells are dependent on mitochondria. Our previous study
showed that the MPT is an essential component in TNFa-
mediated apoptosis in rat hepatocytes and functions upstream
of caspase-3. However, our present study demonstrates differ-
ences in signaling pathways between TNFa- and Fas-mediated
apoptosis in hepatocytes. The time course in the activation of
caspases by Fas was different from those by TNFa. Activation
of caspase-3 and -8 was within 2 h after Jo2 treatment (Fig. 4,
A and B), whereas TNFa activated caspase-3 and -8 after 6 h.
This result is consistent with the report that the Fas signaling
pathway is more rapid and strong in hepatocytes compared
with TNFa (67). These results on the activation of caspases by
Fas indicate that primary mouse hepatocytes act predomi-
nantly as type II cells.
Several pieces of evidence implicate mitochondria in the
FIG. 8. The combination of CsA and
TFZ blocks TNFa- but not Fas-medi-
ated cytochrome c release and cell
death in Ad5IkB-infected hepato-
cytes. A, primary mouse hepatocytes
were infected with Ad5IkB and then
treated with TNFa (30 ng/ml) or Jo2 (0.5
mg/ml) with or without CsA (5 mM) and/or
TFZ (12.5 mM). Cell viability was assessed
at 20 h after treatment by a trypan blue
exclusion test. Data are shown as average
percent viability 6 S.E. B, primary mouse
hepatocytes were treated with TNFa (30
ng/ml) or Jo2 (0.5 mg/ml) with or without
CsA (5 mM) plus TFZ (12.5 mM) after
Ad5IkB infection (30 m.o.i.). S-100 frac-
tions were prepared at the indicated time
points and analyzed for cytochrome c con-
tent by Western blotting. C, primary
mouse hepatocytes were treated with
TNFa (30 ng/ml) or Jo2 (0.5 mg/ml) with
CsA (5 mM) alone, TFZ (12.5 mM) alone, or
both after Ad5IkB infection (30 m.o.i.).
S-100 fractions were prepared 8 or 4 h
after TNFa or Jo2 treatment, respec-
tively, and analyzed for cytochrome c con-
tent by Western blotting.
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FIG. 9. MPT accelerates Fas-mediated apoptosis. A, Ad5IkB-infected hepatocytes were treated with Jo2 (0.5 mg/ml) with/without CsA (5 mM)
plus TFZ (12.5 mM) and then lysed and assayed for caspase 3 activities. Representative data are presented as pmol/mg protein. B and C, cell viability
was assessed by a trypan blue exclusion test after TNFa (B) or Jo2 (C) treatment. Data are shown as average percent viability 6 S.E. D,
Fas-induced hepatotoxicity despite blocking the MPT. Primary mouse hepatocytes were infected with Ad5IkB and then treated with Jo2 (0.5
mg/ml), CsA (5 mM), and TFZ (12.5 mM) and then loaded with calcein and TMRM. Calcein and TMRM fluorescence was monitored simultaneously
over time in living cells by confocal microscopy. Bleb formation and cell shrinkage were observed in the cell that the arrows indicate.
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process of apoptosis. Cytoplasmic events including activation of
protease cascades and MPT participate in the control of nuclear
apoptosis (24, 68, 69). Whether the MPT is essential for cellular
apoptosis remains controversial, because some studies claim
that cytochrome c release during apoptosis occurs without mi-
tochondrial depolarization (68, 70), whereas other studies show
the opposite (34). Here we show cyclosporin A plus trifluoper-
azine prevents the MPT and cytochrome c release by TNFa as
well as apoptosis in mouse hepatocytes, as described previously
in rat hepatocytes (17). These data suggest that mitochondria,
especially the MPT, is essential for hepatocyte apoptosis by
TNFa in mice and rats.
However, the involvement of the MPT in Fas-mediated ap-
optosis has remained elusive. Activation of caspase-1 precedes
the disruption of the mitochondrial inner transmembrane po-
tential, but caspase-3 activation and nuclear apoptosis only
occur in cells in which the mitochondrial transmembrane po-
tential is fully disrupted (71). This indicates that the MPT is
essential for apoptosis downstream of caspase-1 and upstream
of caspase-3. These human CEM-C7.H2 lymphoma cells seem
to be type II cells, as described above (66). In our study cyclos-
porin A plus trifluoperazine prevented the MPT and markedly
decreased cytochrome c release by Fas, but apoptosis was not
blocked in mouse hepatocytes (Figs. 7, 8C, 9A, and 9B). These
results indicate that Fas induces the MPT, which accelerates
but is not necessary for apoptosis.
The mechanism by which activated caspase-8 recruits the
mitochondria to participate in apoptosis is cleaving and acti-
vating Bid. Bid then translocates to the mitochondria to trigger
cytochrome c release (72, 73). Cytochrome c binds to Apaf1,
which in turn self-associates and binds procaspase-9. Transac-
tivation of the complexed procaspase-9 then activates down-
stream caspases. Our results demonstrating Fas-induced MPT
are consistent with an apoptotic pathway that includes the
mitochondria. However, Fas-mediated apoptosis is intact in
Apaf1 knockout T cells (74). Furthermore, while this manu-
script was under review, it was reported that Fas-mediated
apoptosis was delayed rather than prevented in Bid-deficient
hepatocytes (75). These results combined with our study indi-
cate that Fas signaling in hepatocytes activates both a mito-
chondrial independent pathway and a mitochondrial depend-
ent pathway of apoptosis (Fig. 10).
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